Page last updated: 2024-12-08

alpha-(3-aminopropyl)-3,4-dimethoxy-alpha-(1-methylethyl)benzeneacetonitrile

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

alpha-(3-aminopropyl)-3,4-dimethoxy-alpha-(1-methylethyl)benzeneacetonitrile: N-demethylated analog of verapamil [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID161569
SCHEMBL ID2456966
MeSH IDM0067238

Synonyms (23)

Synonym
5-amino-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile
d 620
27487-66-7
5-amino-2-(3,4-dimethoxyphenyl)-2-propan-2-ylpentanenitrile
alpha-(3-aminopropyl)-3,4-dimethoxy-alpha-(1-methylethyl)benzeneacetonitrile
d-620
1ht7nt1n2o ,
unii-1ht7nt1n2o
SCHEMBL2456966
5-amino-2-(3,4-dimethoxyphenyl)-2-isopropylpentanenitrile #
UCWOSFAANAZHKR-UHFFFAOYSA-N
benzeneacetonitrile, .alpha.-(3-aminopropyl)-3,4-dimethoxy-.alpha.-(1-methylethyl)-
4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexylamine
d-620, (+/-)-
1-isopropyl-1-propylamino-(3,4-dimethoxyphenyl)acetonitrile
(2rs)-5-amino-2-(3,4-dimethoxyphenyl)-2-isopropylpentanenitrile
AKOS030228470
5-amino-2-(3,4-dimethoxyphenyl)-2-isopropylpentanenitrile
Q27252431
DTXSID10893324
5-amino-2-(3,4-dimethoxyphenyl)-2-(2-propanyl)pentanenitrile
SB81554
5-amino-2-(3,4-dimethoxyphenyl)-2-(propan-2-yl)pentanenitrile

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" The extent of verapamil bioavailability was directly measured in one patient receiving an intravenous dose as well as an oral one and was found to be 42."( Disposition kinetics and urinary excretion of verapamil and some of its primary metabolites after oral administration in patients with angina pectoris.
Metelitsa, VI; Nikolenko, SA; Piotrovskii, VK; Riabokon, OS; Rumiantsev, DO, 1986
)
0.27
" Following a dose of the slow-release preparation, the drug concentration curves were smoother and the mean bioavailability was lower in comparison with the conventional preparation."( Plasma levels and urinary excretion of verapamil, norverapamil, N-dealkylverapamil (D617), N-dealkylnorverapamil (D620) following oral administration of a slow-release preparation.
Barbieri, E; Cargnelli, G; Ferrari, M; Padrini, R; Piovan, D; Toffoli, M; Trevi, G, 1985
)
0.27

Dosage Studied

ExcerptRelevanceReference
"This study investigated the effect of verapamil metabolites on R- and S-verapamil protein binding in plasma samples collected from subjects prior to rac-verapamil dosing and following single dose and steady state rac-verapamil dosing."( Influence of metabolites on protein binding of verapamil enantiomers.
Akers, WS; Johnson, JA, 1995
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Pathways (1)

PathwayProteinsCompounds
Verapamil Pathway, Pharmacokinetics76

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (50.00)18.7374
1990's4 (40.00)18.2507
2000's1 (10.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.66 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.15 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]